A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and Phase III clinical trials data. [electronic resource]
Producer: 20080403Description: 822-30 p. digitalISSN:- 0020-9996
No physical items for this record
Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.